Document is current
Any future updates will be listed below
-
Authors
Yu, Shengyuan https://orcid.org/0000-0001-8933-088X
Kim, Byung-Kun https://orcid.org/0000-0003-1053-4682
Wang, Hebo https://orcid.org/0000-0002-0598-5772
Zhou, Jiying https://orcid.org/0000-0001-6302-8332
Wan, Qi
Yu, Tingmin https://orcid.org/0000-0001-6124-2917
Lian, Yajun https://orcid.org/0000-0002-0422-9078
Arkuszewski, Michal https://orcid.org/0000-0002-6090-6344
Ecochard, Laurent
Wen, Shihua
Yin, Fangfang
Li, Zheng https://orcid.org/0000-0003-1410-5615
Su, Wendy
Wang, Shuu-Jiun https://orcid.org/0000-0001-5179-5358
-
Funding
Funding for this research was provided by:
This study was fully funded by Novartis Pharma AG. Erenumab is co-developed in partnership with Amgen and Novartis
- License Information
-
More Information
Article History
Received: 8 July 2022
Accepted: 15 September 2022
First Online: 21 November 2022
Declarations
:
: The study protocol, protocol amendments, the informed consent forms, and accompanying materials were reviewed and approved by the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities at each study centre.All participants provided written informed consent before undergoing any study-specific procedures.
: Consent for publication was received.
: Shengyuan Yu, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, and Yajun Lian declare that there is no conflict of interest.Shuu-Jiun Wang has received personal compensation for serving on a Scientific Advisory board for Eli-Lilly and Novartis. He has received personal compensation for serving on as a speaker or moderator for AbbVie, Biogen, Eisai and Pfizer, Taiwan. The institution of Prof. Wang has received research support from Brain Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, Eli-Lilly and Novartis.Byung-Kun Kim has received personal compensation for serving on a Scientific Advisory board for Lundbeck Korea and Novartis. He has received personal compensation for serving on as a speaker or moderator for Allergan Korea, Lilly Korea, Teva Korea, GSK Korea, Lundbeck Korea and SK pharm.Michal Arkuszewski, Laurent Ecochard, Shihua Wen, and Wendy Su are employees of and hold stocks in Novartis.Fangfang Yin and Zheng Li are employees of China Novartis Institutes for Biomedical Research Co Ltd.
